Log in to your Inderes Free account to see all free content on this page.
Genovis
16.16 SEK
-0.25 %
1,633 following
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genovis
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.9 | 27.9 | 130.4 | 32.3 | 28.9 | 27.5 | 40.3 | 128.9 |
| EBITDA | 24.6 | 7.8 | 56.2 | 8.9 | 6.0 | 6.9 | 11.7 | 33.6 |
| EBIT | 22.1 | 5.3 | 45.7 | 6.4 | 3.5 | 3.4 | 8.1 | 21.3 |
| EBIT-% | 67.0 % | 19.1 % | 35.1 % | 19.8 % | 12.0 % | 12.3 % | 20.0 % | 16.5 % |
| Profit before taxes | 22.1 | 5.6 | 46.3 | 6.1 | 3.7 | 9.3 | 7.7 | 26.8 |
| Net income | 13.8 | 4.6 | 32.9 | 3.5 | 5.1 | 8.0 | 6.9 | 23.5 |
Login required
This content is only available for logged in users